The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China

BACKGROUND: Niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved for first/second-line maintenance treatment of ovarian cancer patients with complete or partial response to platinum-based chemotherapy, and multi-line monotherapy in BRCAmt patients or platinum-sensitive recurrence...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Ovarian Res
Main Authors: Ni, Jing, Cheng, Xianzhong, Zhao, Qian, Dai, Zhiqin, Xu, Xia, Guo, Wenwen, Gu, Hongyuan, Zhou, Rui, Wang, Yan, Chen, Xiaoxiang
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC8127179/
https://ncbi.nlm.nih.gov/pubmed/33993885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13048-021-00803-2
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki